Comparison of Continuous Noninvasive and Invasive Intracranial Pressure Measurement--Celda Infusion Subprotocol

NCT ID: NCT01976559

Last Updated: 2017-08-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-11-30
• Study Completion Date: 2014-03-31

Brief Summary

This research is being done to determine the accuracy of two noninvasive methods of measuring the pressure of the spinal fluid, also known as intracranial pressure (ICP).

Detailed Description

Recently, astronauts in long-duration spaceflight have been found to have a syndrome consisting of swelling of the optic nerve, impaired vision, and elevated cerebrospinal fluid pressure (also known as intracranial pressure [ICP]) via lumbar puncture (LP), which is similar to the syndrome of idiopathic intracranial hypertension (IIH). In astronauts, this syndrome is called Visual Impairment/Intracranial Pressure (VIIP). It is not possible to perform an LP on astronauts in space. Noninvasive methods of estimating ICP exist but have not been tested against continuous ICP methods in a patient cohort that is physiologically similar to that of astronauts.

The primary objective of this study is to determine the validity, reliability, accuracy, and precision of two noninvasive methods of ICP measurement (tympanic membrane displacement (TMD, Marchbanks Measurements Systems, UK) and distortion product otoacoustic emissions (DPOAE) in comparison to a reference standard, invasive ICP measurement, in human subjects undergoing diagnostic cerebrospinal fluid (CSF) infusion testing.

The two noninvasive methods are based on the responses of the inner ear and middle ear to changes in ICP. The first method is TMD, which measures tiny movements of the ear drum, and the second is DPOAE, which is routinely used for newborn hearing screening.

Adults with hydrocephalus, shunt malfunction, or other disorders of CSF circulation who have been recommended on the basis of standard clinical criteria to have CSF infusion testing are eligible.

Conditions

Hydrocephalus; Shunt Malfunction

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: SINGLE

Study Groups

Hydrocephalus / Shunt Malfunction

Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing. The interventions include tympanic membrane displacement (TMD) and DPOAE.

Group Type: EXPERIMENTAL

Tympanic Membrane Displacement (TMD)

Intervention Type: DEVICE

The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.

For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.

DPOAE

Intervention Type: DEVICE

DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.

Interventions

Tympanic Membrane Displacement (TMD)

The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.

For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.

Intervention Type: DEVICE

DPOAE

DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.

Intervention Type: DEVICE

Other Intervention Names

Marchbanks MMS-14 TMD Cerebral Cochlear Fluid Pressure (CCFP) Analyzer; Distortion Product Otoacoustic Emissions

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of suspected hydrocephalus or shunt malfunction
• CSF infusion testing has been recommended on the basis of standard clinical criteria
• Capable of providing valid signed informed consent
• Normal middle-ear function as determined by tympanometry
• DPOAE meet criteria that are required for the research
• Acoustic stapedial reflex meets criteria that are required for the research
• Subject is willing and able to participate in the study

Exclusion Criteria

• Subject is pregnant
• Subject lacks decision-making capacity
• Subject is unwilling to participate in the study
• Prior middle-ear disease or surgery, with the exception of tympanostomy tubes that have been removed and are healed
• Participating in the study would significantly delay or interfere with the subject's healthcare
• Subject has excess ear wax that cannot be removed safely and could potentially be pushed onto the ear drum by insertion of the ear plugs needed for the testing
• The TMD or DPOAE do not respond to a change in posture from lying flat to standing up, which means that the anatomic connection between the inner ear and the CSF is absent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Umeå

OTHER

Sponsor Role: collaborator

LifeBridge Health

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael A Williams, MD

Role: PRINCIPAL_INVESTIGATOR

Sinai Hospital of Baltimore / LifeBridge Health

Locations

University of Umea Hospital

Umeå, , Sweden

Countries

Sweden

Other Identifiers

SMST02802

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

IRB 1964

Identifier Type: -

Identifier Source: org_study_id